Raw Materials for Cell and Gene Therapy Summit

Raw materials play a critical role in the development of cell and gene therapies and their quality directly affects the stability, safety, potency, and purity of cell and gene products. However, selection, understanding and lifecycle management of raw materials in line with regulatory expectations remains challenging.

This November, the inaugural Raw Materials for Cell and Gene Therapy Summit will emerge as the industry's exclusive and timely opportunity to address these challenges and bridge the knowledge gap within the raw material community as we delve into critical issues such as supplier selection, material quality, safety assurance and required good manufacturing practices for materials to develop regulatory compliant and high-quality cell and gene therapies.

Navigating through discussions and case studies covering protein and enzyme-based materials, single-use technologies and beyond, join VP, Heads and Directors of Raw Material, Process Development, Quality Control and CMC experts from leading Biopharma, Coordinating Bodies, Suppliers, and CRO's to address the complexity in defining, selecting, using, and adhering to multifaceted regulatory requirements for cell and gene materials towards addressing the unmet clinical need across the globe.

Don't miss out on the opportunity to join the likes of Roche, BMS and Standards Coordinating Body to establish unified definitions for raw materials, ensure global alignment and streamline the development and regulatory approvals of new and innovative cell and gene therapies for patients.

URLs:

Tickets: https://go.evvnt.com/2552221-2?pid=91 

Brochure: https://go.evvnt.com/2552221-3?pid=91 

Prices:

2-Day Conference - Drug Developer - On the Door: USD 2999.00,

2-Day Conference - Academic + Small Biotech - On the Door: USD 2599.00,

2-Day Conference - Solution Provider - On the Door: USD 3699.00

Speakers: Aida Rouzmehr Principal Material Science Engineer- Cell and Gene Therapies Genentech, Anthony Garcia Head of Quality Control Kiromic Biopharma, Ashley Fernandez Quality Control Associate Director of Raw Materials Neurotech Pharmaceuticals, Asif Mahmood Technical Director- Raw Materials Bristol Myers Squibb, Basak Clements Global Head of Materials Sciences Cell and Gene Therapy Roche, Dawn Henke Executive Director Standards Coordinating Body, Houman Dehghani Vice President - Technical Development Cabaletta Bio, Ken Green Executive Director- MSAT Vertex Pharmaceuticals, Lili Belcastro Associate Director, Cell Therapy Development Raw Materials Bristol Myers Squibb, Sarah Powers Senior Stability Manager - Global Quality Control Technical Services uniQure, Scott Jeffers Chief Technology Officer GenSight Biologics, Shayoni Dutta Data Science Manager GlaxoSmithKline, Soleil Grise Biopharma/Pharma Business Development Manager Agilent Technologies, Sona Bairamian Director - Materials Science Atara Biotherapeutics, Tao Cong Director - Raw Material Strategy, Process and Analytical Development BlueRock Therapeutics